Company research
IN8BIO, INC.
CIK 1740279Updated Sep 26, 2026
SecurityINAB · NASDAQ · equity
Name history
Incysus Therapeutics, Inc. · through Sep 20, 2018
INAB price & chart
Loading TradingView…
NASDAQ:INAB on TradingView ↗About the company
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement
Items 1.01, 1.02, 9.01
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 32,282,000Source | 20,944,000Source | 33,709,000Source | 33,039,000Source |
| Property, Plant and Equipment, NetUSD | 1,858,000Source | 2,858,000Source | 3,514,000Source | 4,397,000Source |
| Current assets: | ||||
| Assets, CurrentUSD | 27,880,000Source | 12,578,000Source | 24,625,000Source | 22,234,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 788,000Source | 1,458,000Source | 3,343,000Source | 4,052,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,882,000Source | 3,899,000Source | 3,513,000Source | 4,181,000Source |
| Other Assets, NoncurrentUSD | 146,000Source | 275,000Source | 255,000Source | 255,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,724,000Source | 6,466,000Source | 8,772,000Source | 10,307,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 10,000Source | 7,000Source | 4,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 168,644,000Source | 136,127,000Source | 116,152,000Source | 83,941,000Source |
| Retained Earnings (Accumulated Deficit)USD | -141,096,000Source | -121,656,000Source | -91,219,000Source | -61,212,000Source |
| Stockholders' Equity Attributable to ParentUSD | 27,558,000Source | 14,478,000Source | 24,937,000Source | 22,732,000Source |
| Liabilities and EquityUSD | 32,282,000Source | 20,944,000Source | 33,709,000Source | 33,039,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,161,000Source | 3,083,000Source | 5,393,000Source | 5,822,000Source |
| Operating Lease, Liability, CurrentUSD | 924,000Source | 953,000Source | 820,000Source | 707,000Source |
| Accounts Payable, CurrentUSD | 309,000Source | 389,000Source | 924,000Source | 2,091,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,563,000Source | 3,088,000Source | 2,854,000Source | 3,674,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,633,000Source | 1,047,000Source | 2,955,000Source | 2,342,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -19,440,000Source | -30,437,000Source | -30,007,000Source | -28,521,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,189,000Source | 5,000,000Source | 4,370,000Source | 3,467,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -80,000Source | -535,000Source | -981,000Source | 1,510,000Source |
| Deferred Income Tax Expense (Benefit)USD | -2,417,000Source | -5,553,000Source | -5,741,000Source | -4,512,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -12,712,000Source | -24,149,000Source | -23,340,000Source | -24,121,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | -187,000Source | -600,000Source | -3,705,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 28,638,000Source | 14,184,000Source | 27,044,000Source | 8,988,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 15,926,000Source | -10,152,000Source | 3,104,000Source | -18,838,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 27,312,000Source | 11,386,000Source | 21,538,000Source | 18,434,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 3,189,000Source | 5,000,000Source | 4,370,000Source | 3,467,000Source |
| DepreciationUSD | 1,000,000Source | 976,000Source | 962,000Source | 147,000Source |
| General and Administrative ExpenseUSD | 9,650,000Source | 12,637,000Source | 13,510,000Source | 14,459,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 421,000Source | 230,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -19,440,000Source | -30,437,000Source | -30,007,000Source | -28,521,000Source |
| Operating ExpensesUSD | 19,861,000Source | 30,667,000Source | 30,337,000Source | 28,521,000Source |
| Proceeds from Issuance of Common StockUSD | 8,566,000Source | 3,816,000Source | 14,380,000Source | 9,542,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 0Source | 61,000Source |
| Restructuring CostsUSD | 0Source | 1,100,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -19,440,000Source | -30,437,000Source | -30,337,000Source | -28,521,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -19,440,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -19,440,000Source | -30,437,000Source | -30,007,000Source | -28,521,000Source |
| Earnings Per Share, BasicUSD per share | -4.44Source | -0.57Source | -1Source | -1.36Source |
| Earnings Per Share, DilutedUSD per share | -4.44Source | -0.57Source | -1Source | -1.36Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,374,328Source | 53,547,030Source | 29,864,932Source | 20,967,955Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,374,328Source | 53,547,030Source | 29,864,932Source | 20,967,955Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 9,650,000Source | 12,637,000Source | 13,510,000Source | 14,459,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -19,440,000Source | — | — | — |
| Investment Income, InterestUSD | 421,000Source | 230,000Source | — | — |
| Operating ExpensesUSD | 19,861,000Source | 30,667,000Source | 30,337,000Source | 28,521,000Source |
| Other IncomeUSD | — | 0Source | 330,000Source | — |
| Research and Development ExpenseUSD | 10,211,000Source | 16,962,000Source | 16,827,000Source | 14,062,000Source |
| Restructuring CostsUSD | 0Source | 1,100,000Source | — | — |
Filing attachments
inab-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 inab-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half of 2026 • Presented updated data at ASCO 2026 demonstrating median overall survival (mOS) exceeding 19.5 months a…
Read attachment ↗inab-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 4 inab-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights • Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 • Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 • Hosting R&D Day on May 21, 2026 in New York City NEW YORK, May 7, 2026…
Read attachment ↗